A standardised method for interpreting the association drug resistance inMycobacterium tuberculosis

European Respiratory Journal

50, 1701354

DOI: 10.1183/13993003.01354-2017

Citation Report

#	Article	IF	Citations
1	Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens. European Respiratory Journal, 2017, 50, 1702292.	6.7	9
2	Mycobacterial biomaterials and resources for researchers. Pathogens and Disease, 2018, 76, .	2.0	14
3	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017Âupdate. European Respiratory Journal, 2018, 51, 1702678.	6.7	50
4	Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries. European Respiratory Journal, 2018, 51, 1800387.	6.7	29
5	Evaluation of pyrosequencing for extensive drug resistance-defining anti-tuberculosis drugs for use in public healthcare. Tuberculosis, 2018, 110, 86-90.	1.9	3
6	Use of whole genome sequencing in surveillance of drug resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2018, 16, 433-442.	4.4	22
7	Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2018, 56, .	3.9	88
8	Dissecting whole-genome sequencing-based online tools for predicting resistance in Mycobacterium tuberculosis : can we use them for clinical decision guidance?. Tuberculosis, 2018, 110, 44-51.	1.9	25
9	Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infectious Diseases, The, 2018, 18, 675-683.	9.1	119
10	Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infectious Diseases, The, 2018, 18, e199-e210.	9.1	244
11	Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. European Respiratory Journal, 2018, 51, 1702571.	6.7	7
12	Drug-resistant tuberculosis: is India ready for the challenge?. BMJ Global Health, 2018, 3, e000971.	4.7	36
13	First insights on the genetic diversity of MDR Mycobacterium tuberculosis in Lebanon. BMC Infectious Diseases, 2018, 18, 710.	2.9	7
14	The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2018, 73, 2667-2674.	3.0	17
15	Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. New England Journal of Medicine, 2018, 379, 1403-1415.	27.0	405
16	Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports, 2018, 8, 15382.	3.3	75
17	Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathogens, 2018, 14, e1007297.	4.7	43
18	Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 2018, 23, 1098-1113.	2.3	62

#	Article	IF	Citations
19	Whole genome sequencing of Mycobacterium tuberculosis. European Respiratory Journal, 2018, 52, 1801163.	6.7	35
20	Perspectives for personalized therapy for patients with multidrugâ€resistant tuberculosis. Journal of Internal Medicine, 2018, 284, 163-188.	6.0	33
21	Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	62
22	Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania. Scientific Reports, 2018, 8, 9676.	3.3	27
23	Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
24	Characterization of Mutations Conferring Resistance to Rifampin in Mycobacterium tuberculosis Clinical Strains. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
25	Mixed Mycobacterium tuberculosisâ€“Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. Journal of Infectious Diseases, 2018, 218, 1974-1982.	4.0	32
26	Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Current Opinion in Pharmacology, 2018, 42, 7-15.	3.5	121
27	Evaluation of Whole-Genome Sequence Method to Diagnose Resistance of 13 Anti-tuberculosis Drugs and Characterize Resistance Genes in Clinical Multi-Drug Resistance Mycobacterium tuberculosis Isolates From China. Frontiers in Microbiology, 2019, 10, 1741.	3.5	53
28	Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India. Scientific Reports, 2019, 9, 10283.	3.3	32
29	Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014â€“2016). BMC Pulmonary Medicine, 2019, 19, 124.	2.0	13
30	Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Medicine, 2019, 11, 45.	8.2	88
32	Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests. Journal of Infectious Diseases, 2019, 220, S126-S135.	4.0	10
33	High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. PLoS Medicine, 2019, 16, e1002961.	8.4	62
34	Whole-Genome Sequencing in Relation to Resistance of Mycobacterium Tuberculosis. Acta Medica Martiniana, 2019, 19, 12-21.	0.3	3
35	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	10.7	92
36	Management of drug-resistant tuberculosis. Lancet, The, 2019, 394, 953-966.	13.7	186
37	Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	59

#	Article	IF	Citations
38	TB DEPOT (Data Exploration Portal): A multi-domain tuberculosis data analysis resource. PLoS ONE, 2019, 14, e0217410.	2.5	13
39	Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nature Reviews Microbiology, 2019, 17, 533-545.	28.6	237
41	Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
42	GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nature Communications, 2019, 10, 2128.	12.8	111
43	Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	32
44	Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Medicine, 2019, 16, e1002794.	8.4	49
45	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office forÂEurope. European Respiratory Journal, 2019, 53, 1900391.	6.7	81
46	Speeding up the diagnosis of multidrug-resistant tuberculosis in a high-burden region with the use of a commercial line probe assay. Jornal Brasileiro De Pneumologia, 2019, 45, e20180128.	0.7	7
47	Cryptic Resistance Mutations Associated With Misdiagnoses of Multidrug-Resistant Tuberculosis. Journal of Infectious Diseases, 2019, 220, 316-320.	4.0	19
48	Diagnosis of pulmonary tuberculosis. Journal of the Korean Medical Association, 2019, 62, 18.	0.3	0
49	Building the Framework for Standardized Clinical Laboratory Reporting of Next-generation Sequencing Data for Resistance-associated Mutations in Mycobacterium tuberculosis Complex. Clinical Infectious Diseases, 2019, 69, 1631-1633.	5.8	10
50	Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis. PLoS ONE, 2019, 14, e0212798.	2.5	14
51	Deciphering Within-Host Microevolution of Mycobacterium tuberculosis through Whole-Genome Sequencing: the Phenotypic Impact and Way Forward. Microbiology and Molecular Biology Reviews, 2019, 83, .	6.6	43
52	Whole-Genome Sequencing of Drug-Resistant Mycobacterium tuberculosis Strains, Tunisia, 2012â€“2016. Emerging Infectious Diseases, 2019, 25, 538-546.	4.3	17
53	Drug-Resistant Tuberculosis, Lebanon, 2016 â€“ 2017. Emerging Infectious Diseases, 2019, 25, 564-568.	4.3	15
54	Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infectious Diseases, The, 2019, 19, 298-307.	9.1	45
56	A Rare D94F Change in gyrA Gene of Multidrug-Resistant Mycobacterium tuberculosis Possibly Contributing to an Unfavorable Treatment Outcome. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	0
57	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e93-e142.	5.6	282

#	Article	IF	Citations
58	Minority Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 789-791.	2.9	11
59	Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis. Diagnostic Microbiology and Infectious Disease, 2019, 94, 147-154.	1.8	5
60	Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohortÂstudy. European Respiratory Journal, 2019, 53, 1801770.	6.7	21
61	Genome-Based Prediction of Bacterial Antibiotic Resistance. Journal of Clinical Microbiology, 2019, 57, .	3.9	221
62	Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infection, Genetics and Evolution, 2019, 72, 169-182.	2.3	39
63	Advances in the molecular diagnosis of tuberculosis: From probes to genomes. Infection, Genetics and Evolution, 2019, 72, 93-112.	2.3	46
64	Mutations of Mycobacterium tuberculosis induced by anti-tuberculosis treatment result in metabolism changes and elevation of ethambutol resistance. Infection, Genetics and Evolution, 2019, 72, 151-158.	2.3	10
65	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. Clinical Infectious Diseases, 2020, 70, 1774-1780.	5.8	59
66	Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 415-426.	2.9	5
67	Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. BMC Infectious Diseases, 2020, 20, 19.	2.9	6
68	A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB. PLoS ONE, 2020, 15, e0227215.	2.5	10
69	An optimized genomic VCF workflow for precise identification of Mycobacterium tuberculosis cluster from cross-platform whole genome sequencing data. Infection, Genetics and Evolution, 2020, 79, 104152.	2.3	6
70	Tuberculosis, HIV, and viral hepatitis diagnostics in eastern Europe and central Asia: high time for integrated and people-centred services. Lancet Infectious Diseases, The, 2020, 20, e47-e53.	9.1	13
71	First insights into circulating XDR and pre-XDR Mycobacterium tuberculosis in Southern Brazil. Infection, Genetics and Evolution, 2020, 78, 104127.	2.3	7
72	Molecular Diagnosis of Drug Resistance in Mycobacterium tuberculosis. Advances in Molecular Pathology, 2020, 3, 87-95.	0.4	0
73	Interpreting k-merâ€“based signatures for antibiotic resistance prediction. GigaScience, 2020, 9, .	6.4	17
74	Prediction of rifampicin resistance beyond the RRDR using structure-based machine learning approaches. Scientific Reports, 2020, 10, 18120.	3.3	30
75	Transmission of Mycobacterium tuberculosis presenting unusually high discordance between genotypic and phenotypic resistance to rifampicin in an endemic tuberculosis setting. Tuberculosis, 2020, 125, 102004.	1.9	7

#	Article	IF	Citations
76	The Performance of the Abbott Real Time MTB RIF/INH Compared to the MTBDRplus V2 for the Identification of MDR-TB Among Isolates . Infection and Drug Resistance, 2020, Volume 13, 3301-3308.	2.7	3
77	Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis. Clinical Infectious Diseases, 2021, 73, e3511-e3517.	5.8	8
79	LncRNA MEG3 control Mycobacterium Tuberculosis infection via controlled MiR-145-5p expression and modulation of macrophages proliferation. Microbial Pathogenesis, 2020, 149, 104550.	2.9	10
80	Genomic Analysis Identifies Mutations Concerning Drug-Resistance and Beijing Genotype in Multidrug-Resistant Mycobacterium tuberculosis Isolated From China. Frontiers in Microbiology, 2020, 11, 1444.	3.5	13
81	Update of SEPAR Guideline â€œDiagnosis and Treatment of Drug-Resistant Tuberculosisâ€• Archivos De Bronconeumologia, 2020, 56, 514-521.	0.8	3
82	Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs Among Mycobacterium tuberculosis by a Reverse Dot Blot Hybridization Assay . Infection and Drug Resistance, 2020, Volume 13, 4091-4104.	2.7	3
83	New Xpert MTB/XDR: added value and future in the field. European Respiratory Journal, 2020, 56, 2003616.	6.7	15
84	Use of a Whole Genome Sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017â€“2019: an ECDC pilot study. European Respiratory Journal, 2021, 57, 2002272.	6.7	27
85	Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. Journal of Clinical Microbiology, 2020, 58, .	3.9	57
86	Genomic epidemiology of Mycobacterium tuberculosis in Santa Catarina, Southern Brazil. Scientific Reports, 2020, 10, 12891.	3.3	6
87	How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	18
88	Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: A retrospective cohort study. PLoS ONE, 2020, 15, e0236264.	2.5	10
89	Whole-genome sequencing of Mycobacterium tuberculosis directly from clinical samples for high-resolution genomic epidemiology and drug resistance surveillance: an observational study. Lancet Microbe, The, 2020, 1, e175-e183.	7.3	42
90	Laboratory Evaluation of a Lateral-Flow Cell for Molecular Detection of First-Line and Second-Line Antituberculosis Drug Resistance. Journal of Clinical Microbiology, 2020, 58, .	3.9	3
91	Novel Assays/Applications for Patients Suspected of Mycobacterial Diseases. Clinics in Laboratory Medicine, 2020, 40, 535-552.	1.4	1
92	Drug-Resistant Tuberculosis. Infectious Disease Clinics of North America, 2020, 34, 863-886.	5.1	9
93	Detection of drug resistant Mycobacterium tuberculosis by high-throughput sequencing of DNA isolated from acid fast bacilli smears. PLoS ONE, 2020, 15, e0232343.	2.5	7
94	Whole-genome sequencing and Mycobacterium tuberculosis: Challenges in sample preparation and sequencing data analysis. Tuberculosis, 2020, 123, 101946.	1.9	13

#	Article	IF	Citations
95	Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Medicine, 2020, 12, 27.	8.2	58
96	Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China. Journal of Global Antimicrobial Resistance, 2020, 22, 290-295.	2.2	10
97	Rapid Pyrazinamide Drug Susceptibility Testing using a Closed-Tube PCR Assay of the Entire pncA gene. Scientific Reports, 2020, 10, 4234.	3.3	4
98	Drug-Resistant Tuberculosis 2020: Where We Stand. Applied Sciences (Switzerland), 2020, 10, 2153.	2.5	46
99	Targeted next-generation sequencing of sputum for diagnosis ofÂdrug-resistant TB: results of a national survey in DemocraticÂRepublic of theÂCongo. Scientific Reports, 2020, 10, 10786.	3.3	13
100	Genome sequencing of Mycobacterium tuberculosis clinical isolates revealed isoniazid resistance mechanisms undetected by conventional molecular methods. International Journal of Antimicrobial Agents, 2020, 56, 106068.	2.5	5
101	Structure guided prediction of Pyrazinamide resistance mutations in pncA. Scientific Reports, 2020, 10, 1875.	3.3	54
102	Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania. BMC Genomics, 2020, 21, 174.	2.8	28
103	Genotypic characterization of â€¯inferredâ€™ rifampin mutations in GenoType MTBDRplus assay and its association with phenotypic susceptibility testing of Mycobacterium tuberculosis.. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114995.	1.8	6
104	Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran. Journal of Clinical Medicine, 2020, 9, 465.	2.4	20
105	Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Medicine, 2020, 17, e1003008.	8.4	74
106	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. International Journal of Infectious Diseases, 2020, 92, S5-S9.	3.3	13
107	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	3.3	126
108	Improved treatment outcome of multidrug-resistant tuberculosis with the use of a rapid molecular test to detect drug resistance in China. International Journal of Infectious Diseases, 2020, 96, 390-397.	3.3	9
109	Accuracy of a reverse dot blot hybridization assay for simultaneous detection of the resistance of four anti-tuberculosis drugs in Mycobacterium tuberculosis isolated from China. Infectious Diseases of Poverty, 2020, 9, 38.	3.7	14
110	Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. European Respiratory Journal, 2021, 57, 2001796.	6.7	47
111	Emergence of Specific gyrA Mutations Associated High-Level Fluoroquinolone-Resistant Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Cases in North India. Microbial Drug Resistance, 2021, 27, 647-651.	2.0	10
112	Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum. Journal of Clinical Microbiology, 2021, 59, .	3.9	43

#	Article	IF	Citations
113	Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. European Respiratory Journal, 2021, 57, 2002338.	6.7	58
114	The overview and perspectives of biosensors and Mycobacterium tuberculosis: A systematic review. Journal of Cellular Physiology, 2021, 236, 1730-1750.	4.1	15
115	Microbiological Diagnosis of Tuberculosis Disease. , 2021, , 87-96.		0
116	Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis. Computational and Structural Biotechnology Journal, 2021, 19, 2423-2446.	4.1	9
117	WGS for Bacterial Identification and Susceptibility Testing in the Clinical Lab. , 2021, , 25-44.		1
118	Improving tuberculosis surveillance by detecting international transmission using publicly available whole genome sequencing data. Eurosurveillance, 2021, 26, .	7.0	9
119	Identification and Characterization of Mycobacterial Species Using Whole-Genome Sequences. Methods in Molecular Biology, 2021, 2314, 399-457.	0.9	0
120	OUP accepted manuscript. JAC-Antimicrobial Resistance, 2021, 3, dlab101.	2.1	4
121	Identification of drug resistance mutations among Mycobacterium bovis lineages in the Americas. PLoS Neglected Tropical Diseases, 2021, 15, e0009145.	3.0	7
122	Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. Journal of Clinical Microbiology, 2021, 59, .	3.9	13
124	Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection. International Journal of Infectious Diseases, 2021, 113, S48-S54.	3.3	31
125	Accuracy of the Truenat MTB-RIF Dx assay for detection of rifampicin resistance-associated mutations. Tuberculosis, 2021, 127, 102064.	1.9	7
126	Clinical and public health utility of Mycobacterium tuberculosis whole genome sequencing. International Journal of Infectious Diseases, 2021, 113, S40-S42.	3.3	15
127	On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex. Journal of Clinical Microbiology, 2021, 59, .	3.9	14
128	Tale of compounding oddities. BMJ Case Reports, 2021, 14, e237382.	0.5	1
130	Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study. Infection and Drug Resistance, 2021, Volume 14, 1089-1104.	2.7	6
131	Tuberculosis multirresistentediez aÃ±os despuÃ©s. Medicina ClÃnica, 2021, 156, 393-401.	0.6	5
132	Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing. Clinical Infectious Diseases, 2021, 73, 1194-1202.	5.8	21

#	Article	IF	Citations
133	Predicting rifampicin resistance mutations in bacterial RNA polymerase subunit beta based on majority consensus. BMC Bioinformatics, 2021, 22, 210.	2.6	5
134	Multi-drug resistant tuberculosis, ten years later. Medicina ClÃnica (English Edition), 2021, 156, 393-401.	0.2	2
135	Evaluation of the Roche cobas MTB and MTB-RIF/INH Assays in Samples from Germany and Sierra Leone. Journal of Clinical Microbiology, 2021, 59, .	3.9	5
136	Performance of the GenoType MTBDRsl V 2.0 for detecting second-line drugs resistance of Mycobacterium tuberculosis isolates in Tunisia. Research in Microbiology, 2021, 172, 103816.	2.1	2
137	A Bioinformatics Whole-Genome Sequencing Workflow for Clinical Mycobacterium tuberculosis Complex Isolate Analysis, Validated Using a Reference Collection Extensively Characterized with Conventional Methods and In Silico Approaches. Journal of Clinical Microbiology, 2021, 59, .	3.9	18
138	Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe2+ Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide. Frontiers in Molecular Biosciences, 2021, 8, 633365.	3.5	5
139	Assessment of the GenoType MTBDRsl VER 2.0 compared to the phenotypic drug susceptibility testing and whole genome sequencing for the rapid detection of resistance to fluoroquinolone and second-line injectable drugs among rifampicin-resistant Mycobacterium tuberculosis isolates. Archives of Microbiology, 2021, 203, 3989-3996.	2.2	7
140	Should treatment of low-level rifampicin mono-resistant tuberculosis be different?. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 23, 100222.	1.3	5
143	Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China. BMC Infectious Diseases, 2021, 21, 605.	2.9	8
144	Melting the eis : Nondetection of Kanamycin Resistance Markers by Routine Diagnostic Tests and Identification of New eis Promoter Variants. Antimicrobial Agents and Chemotherapy, 2021, 65, e0250220.	3.2	0
145	Heterogeneous Streptomycin Resistance Level Among Mycobacterium tuberculosis Strains From the Same Transmission Cluster. Frontiers in Microbiology, 2021, 12, 659545.	3.5	10
147	Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0261720.	3.2	11
148	Correlating genetic mutations with isoniazid phenotypic levels of resistance in Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis in a high burden setting. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2551-2561.	2.9	5
149	Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe, The, 2021, 2, e604-e616.	7.3	32
150	GenTB: A user-friendly genome-based predictor for tuberculosis resistance powered by machine learning. Genome Medicine, 2021, 13, 138.	8.2	27
151	Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Antimicrobial Agents and Chemotherapy, 2021, 65, e0036421.	3.2	7
152	Age and sex distribution of Mycobacterium tuberculosis infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF. BMC Infectious Diseases, 2021, 21, 781.	2.9	6
153	Prevalence and Molecular Characteristics Based on Whole Genome Sequencing of Mycobacterium tuberculosis Resistant to Four Anti-Tuberculosis Drugs from Southern Xinjiang, China. Infection and Drug Resistance, 2021, Volume 14, 3379-3391.	2.7	7

#	Article	IF	Citations
154	INGOT-DR: an interpretable classifier for predicting drug resistance in M. tuberculosis. Algorithms for Molecular Biology, 2021, 16, 17.	1.2	9
155	Analytical performance of the Xpert MTB/XDRÂ® assay for tuberculosis and expanded resistance detection. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115397.	1.8	12
156	Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance. Clinical Microbiology and Infection, 2021, 27, 1351.e1-1351.e4.	6.0	6
157	Analysis of the application of a gene chip method for detecting Mycobacterium tuberculosis drug resistance in clinical specimens: a retrospective study. Scientific Reports, 2021, 11, 17951.	3.3	5
159	Characterization of Mutations Associated with Streptomycin Resistance in Multidrug-Resistant Mycobacterium tuberculosis in Zambia. Antibiotics, 2021, 10, 1169.	3.7	9
163	Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil. International Journal of Antimicrobial Agents, 2021, 58, 106401.	2.5	12
164	Clinical Interpretation of Drug Susceptibility Tests in Tuberculosis. Current Respiratory Medicine Reviews, 2021, 16, 102-112.	0.2	1
165	A computational perspective on the dynamic behaviour of recurrent drug resistance mutations in the pncA gene from Mycobacterium tuberculosis. RSC Advances, 2021, 11, 2476-2486.	3.6	8
166	Advances in the diagnosis of tuberculosis- Journey from smear microscopy to whole genome sequencing. Indian Journal of Tuberculosis, 2020, 67, S61-S68.	0.7	5
167	Discordant bioinformatic predictions of antimicrobial resistance from whole-genome sequencing data of bacterial isolates: an inter-laboratory study. Microbial Genomics, 2020, 6, .	2.0	69
168	Benchmarking bacterial genome-wide association study methods using simulated genomes and phenotypes. Microbial Genomics, 2020, 6, .	2.0	38
174	Laboratory diagnosis of tuberculosis. , 0, , 99-115.		1
175	Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe. Wellcome Open Research, 2019, 4, 191.	1.8	103
176	Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB. PLoS ONE, 2020, 15, e0244829.	2.5	17
177	Molecular characterization of pre-extensive drug resistant Mycobacterium tuberculosis in Northeast Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2020, 62, e4.	1.1	4
179	Focusing on DNA Repair and Damage Tolerance Mechanisms in Mycobacterium tuberculosis: An Emerging Therapeutic Theme. Current Topics in Medicinal Chemistry, 2020, 20, 390-408.	2.1	8
180	A large scale evaluation of TBProfiler and Mykrobe for antibiotic resistance prediction in Mycobacterium tuberculosis. PeerJ, 2019, 7, e6857.	2.0	18
181	Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infectious Diseases, The, 2022, 22, 242-249.	9.1	47

#	Article	IF	Citations
182	Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola. BMC Infectious Diseases, 2021, 21, 1056.	2.9	9
183	A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0151421.	3.2	10
185	Drug-Resistant Tuberculosis and HIV. , 2019, , 203-237.		0
187	Molecular Basis of Drug Resistance in Mycobacteria. , 2019, , 3-31.		1
190	Personalized Approach as a Basis for the Future Diagnosis of Tuberculosis (Literature Review). Acta Biomedica Scientifica, 2019, 4, 127-137.	0.2	0
191	Bridging the TB data gap: in silico extraction of rifampicin-resistant tuberculosis diagnostic test results from whole genome sequence data. PeerJ, 2019, 7, e7564.	2.0	4
194	Predictive analysis of the situation of tuberculosis in the world based on the results of the annual WHO report. Infusion & Chemotherapy, 2019, , 10-17.	0.1	0
195	Combination of Xpert MTB/RIF and MTBDRplus for Diagnosing Tuberculosis in a Chinese District. Medical Science Monitor, 2020, 26, e923508.	1.1	1
196	A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TBÂ® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Frontiers in Cellular and Infection Microbiology, 2021, 11, 707244.	3.9	14
198	Achievements and complex issues for tuberculosis in Ukraine (consolidated view from different) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	3
200	Next-generation sequencing to characterise pyrazinamide resistance in Mycobacterium tuberculosis isolates from two Balkan countries. Journal of Global Antimicrobial Resistance, 2022, 29, 507-512.	2.2	6
201	Retrospective evaluation of routine whole genome sequencing of Mycobacterium tuberculosis at the Belgian National Reference Center, 2019. Acta Clinica Belgica, 2022, 77, 853-860.	1.2	5
202	Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2022, 60, JCM0190721.	3.9	6
203	An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis. Communications Biology, 2021, 4, 1322.	4.4	5
204	A Rapid Drug Resistance Genotyping Workflow for Mycobacterium tuberculosis, Using Targeted Isothermal Amplification and Nanopore Sequencing. Microbiology Spectrum, 2021, 9, e0061021.	3.0	19
205	Strengths and caveats of identifying resistance genes from whole genome sequencing data. Expert Review of Anti-Infective Therapy, 2022, 20, 533-547.	4.4	7
206	SAM-TB: a whole genome sequencing data analysis website for detection of Mycobacterium tuberculosis drug resistance and transmission. Briefings in Bioinformatics, 2022, 23, .	6.5	26
207	Quadriceps physiological response during the 1-min sit-to-stand test in people with severe COPD and healthy controls. Scientific Reports, 2022, 12, 794.	3.3	4

#	Article	IF	Citations
208	Drug susceptibility testing of Mycobacterium tuberculosis using next generation sequencing and Mykrobe software. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2022, 98, 697-705.	1.0	0
209	Experimental Confirmation that an UncommonrrsGene Mutation (g878a) of Mycobacterium tuberculosis Confers Resistance to Streptomycin. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0191521.	3.2	3
210	Application of Amplicon-Based Targeted NGS Technology for Diagnosis of Drug-Resistant Tuberculosis Using FFPE Specimens. Microbiology Spectrum, 2022, 10, e0135821.	3.0	3
211	Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead. BioMed Research International, 2022, 2022, 1-12.	1.9	15
212	Direct Molecular Detection of Drug-Resistant Tuberculosis from Transported Bio-Safe Dried Sputum on Filter-Paper. Current Microbiology, 2022, 79, 110.	2.2	0
213	Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis. European Respiratory Journal, 2022, 60, 2200239.	6.7	29
214	Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field. Frontiers in Microbiology, 2022, 13, 775030.	3.5	22
215	Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2022, 66, e0202721.	3.2	4
217	The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe, The, 2022, 3, e265-e273.	7.3	114
218	The Neglected Contribution of Streptomycin to the Tuberculosis Drug Resistance Problem. Genes, 2021, 12, 2003.	2.4	4
219	Mycobacterium tuberculosis Lineages Associated with Mutations and Drug Resistance in Isolates from India. Microbiology Spectrum, 2022, 10, e0159421.	3.0	10
231	Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. Tuberculosis, 2022, 135, 102209.	1.9	9
232	Intra-host genetic population diversity: Role in emergence and persistence of drug resistance among Mycobacterium tuberculosis complex minor variants. Infection, Genetics and Evolution, 2022, 101, 105288.	2.3	1
233	Whole genome sequencing analysis to evaluate the influence of T2DM on polymorphisms associated with drug resistance in M. tuberculosis. BMC Genomics, 2022, 23, .	2.8	1
234	Minos: variant adjudication and joint genotyping of cohorts of bacterial genomes. Genome Biology, 2022, 23, .	8.8	11
235	Non-actionable results, accuracy and effect of the first- and second-line line probe assays for diagnosing drug resistant tuberculosis, including on smear-negative specimens, in a high-volume laboratory. Clinical Infectious Diseases, 0, , .	5.8	3
236	Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study. Lancet Microbe, The, 2022, 3, e672-e682.	7.3	21
237	Genome-wide association studies of global Mycobacterium tuberculosis resistance to 13 antimicrobials in 10,228 genomes identify new resistance mechanisms. PLoS Biology, 2022, 20, e3001755.	5.6	27

#	Article	IF	Citations
238	Predicting antibiotic resistance in complex protein targets using alchemical free energy methods. Journal of Computational Chemistry, 0, , .	3.3	2
239	Evaluation of whole-genome sequence to predict drug resistance of nine anti-tuberculosis drugs and characterize resistance genes in clinical rifampicin-resistant Mycobacterium tuberculosis isolates from Ningbo, China. Frontiers in Public Health, 0, 10, .	2.7	1
240	A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. PLoS Biology, 2022, 20, e3001721.	5.6	37
241	Rapid Identification of Drug Resistance and Phylogeny in M. tuberculosis, Directly from Sputum Samples. Microbiology Spectrum, 2022, 10, .	3.0	7
243	â€œUpcyclingâ€•known molecules and targets for drug-resistant TB. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	1
244	In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis. Scientific Reports, 2022, 12, .	3.3	1
245	Regional distribution of Mycobacterium tuberculosis infection and resistance to rifampicin and isoniazid as determined by high-resolution melt analysis. BMC Infectious Diseases, 2022, 22, .	2.9	1
246	Use of Whole-Genome Sequencing for Detection of Antimicrobial Resistance: Mycobacterium tuberculosis, a Model Organism. Clinical Laboratory Science: Journal of the American Society for Medical Technology, 2019, 32, ascls.2019001784.	0.1	0
247	Genomic analysis of Mycobacterium tuberculosis variant bovis strains isolated from bovine in the state of Mato Grosso, Brazil. Frontiers in Veterinary Science, 0, 9, .	2.2	1
248	Evaluation of xpert Mycobacterium tuberculosis rifampicin for tuberculosis diagnosis in a reference laboratory. International Journal of Mycobacteriology, 2022, 11, 435.	0.6	0
249	CURRENT APPROACHES TO CONTROL OF ISONIAZID-RESISTANT TUBERCULOSIS. , 2022, 50, 25-31.		0
250	rpoB Mutations are Associated with Variable Levels of Rifampin and Rifabutin Resistance in Mycobacterium tuberculosis. Infection and Drug Resistance, 0, Volume 15, 6853-6861.	2.7	2
251	Experiences from 4 Years of Organization of an External Quality Assessment for Mycobacterium tuberculosis Whole-Genome Sequencing in the European Union/European Economic Area. Microbiology Spectrum, 2023, 11, .	3.0	2
252	Clinical utility of target-based next-generation sequencing for drug-resistant TB. International Journal of Tuberculosis and Lung Disease, 2023, 27, 41-48.	1.2	4
253	Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	1
254	Drug-Resistant Tuberculosis on the Balkan Peninsula: Determination of Drug Resistance Mechanisms with Xpert MTB/XDR and Whole-Genome Sequencing Analysis. Microbiology Spectrum, 2023, 11, .	3.0	5
255	Omics analysis of Mycobacterium tuberculosis isolates uncovers Rv3094c, an ethionamide metabolism-associated gene. Communications Biology, 2023, 6, .	4.4	0
256	Investigation of Multi-Subunit Mycobacterium tuberculosis DNA-Directed RNA Polymerase and Its Rifampicin Resistant Mutants. International Journal of Molecular Sciences, 2023, 24, 3313.	4.1	4

#	Article	IF	Citations
257	Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infectious Diseases, The, 2023, 23, e122-e137.	9.1	14
258	The effects of standardised versus individualised seat height on 1-minute sit-to-stand test performance in healthy individuals: a randomised crossover trial. European Journal of Applied Physiology, 0, , .	2.5	0
259	Diagnostic performance of the GenoType MTBDRplus VER 2.0 line probe assay for the detection of isoniazid resistant Mycobacterium tuberculosis in Ethiopia. PLoS ONE, 2023, 18, e0284737.	2.5	1
260	Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients. Journal of Clinical Microbiology, 2023, 61, .	3.9	0
261	A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant. PLoS ONE, 2023, 18, e0287019.	2.5	1
263	Whole-genome sequencing and transcriptome-characterized in vitro evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Microbial Genomics, 2023, 9, .	2.0	1
264	Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2023, 33, 100387.	1.3	0
266	Genome-Based Prediction of Bacterial Antibiotic Resistance. Livestock Diseases and Management, 2023, , 215-230.	0.5	0
267	Preliminary Phytochemical Screening and Study of In vitro Antibacterial Activity on H37RV Strain using roots of Ziziphus nummularia. Research Journal of Pharmacognosy and Phytochemistry, 2023, , 198-202.	0.8	0
268	Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy. Microbiology Spectrum, 0, , .	3.0	0
269	Implementation of national whole-genome sequencing of Mycobacterium tuberculosis, National Public Health Laboratory, Singapore, 2019â€"2022. Microbial Genomics, 2023, 9, .	2.0	0
270	Role of the first WHO mutation catalogue in the diagnosis of antibiotic resistance in Mycobacterium tuberculosis in the Valencia Region, Spain: a retrospective genomic analysis. Lancet Microbe, The, 2023, , .	7.3	0
271	Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis. Lancet Microbe, The, 2024, 5, e164-e172.	7.3	1
272	Whole genome sequencing for the prediction of resistant tuberculosis strains from northern India. Indian Journal of Medical Microbiology, 2024, 48, 100537.	0.8	0
273	Drug-resistant tuberculosis: a persistent global health concern. Nature Reviews Microbiology, 0, , .	28.6	0